Michael Addition-Based Neoadjuvant for Enhanced Cancer Immunotherapy.

Area of Science:

• Immunology
• Materials Science
• Oncology

Background:

• Cancer immunotherapy faces challenges with inefficient antigen presentation by dendritic cells (DCs).
• The immunosuppressive tumor microenvironment (ITME) further impairs DC function.
• Limited antigen uptake by DCs hinders effective anti-tumor immune responses.

Purpose of the Study:

• To investigate the potential of cinnamaldehyde-grafted polyethylenimine (PC) as a neoadjuvant for cancer immunotherapy.
• To enhance antigen capture, DC maturation, and antigen presentation in the tumor microenvironment.
• To potentiate anti-tumor immune responses in low immunogenic breast cancer models.

Main Methods:

• Development of cinnamaldehyde-grafted polyethylenimine (PC) nanoparticles.
• Utilizing PC to capture tumor antigens and enhance DC-antigen crosstalk.
• Employing in situ Michael addition reaction to deplete intracellular glutathione, activating the NLRP3 inflammasome pathway.
• Assessing DC maturation and CD8+ T cell infiltration in a murine breast cancer model.

Main Results:

• PC neoadjuvant effectively captured tumor antigens generated during chemotherapy.
• PC treatment led to significant DC maturation (46%) by activating the NLRP3 pathway.
• PC triggered antigen release and augmented antigen presentation.
• A 53% ratio of CD8+ T cell infiltration was observed in the treated murine breast cancer model.

Conclusions:

• Cinnamaldehyde-grafted polyethylenimine (PC) shows promise as a neoadjuvant to overcome immune evasion in cancer.
• PC enhances DC function and antigen presentation, thereby boosting anti-tumor immunity.
• This approach offers a potential strategy to improve immunotherapy efficacy in challenging cancer types.